Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Dysregulated activation of the CDK4/6 kinases is a hallmark of most mammary-derived carcinomas. ATP-competitive inhibitors against this complex have been recently advanced in the clinic and have shown significant activity, particularly against tumors driven by the estrogen receptor (ER). However, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, C, Li, Z, Bhatt, T, Dickler, M, Giri, D, Scaltriti, M, Baselga, J, Rosen, N, Chandarlapaty, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393973/
https://www.ncbi.nlm.nih.gov/pubmed/27748766
http://dx.doi.org/10.1038/onc.2016.379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393973/
https://www.ncbi.nlm.nih.gov/pubmed/27748766
http://dx.doi.org/10.1038/onc.2016.379

Ejemplares similares